Abstract
All-trans retinoic acid (ATRA) induces differentiation of NB4 and HL-60 leukemia cells, but not R4 and HL-60/Res cells. Three agents used in cancer therapy, doxorubicin (Dox), arsenic trioxide (As2O3) and paclitaxel, induce apoptosis, but not differentiation, in all of these cell lines. The induction of apoptosis by these agents is decreased in ATRA-pretreated NB4 and HL-60 cells, but not in ATRA-pretreated R4 and HL-60/Res cells. The level of Bcl-2 protein is decreased by ATRA treatment in NB4, HL-60 and HL-60/Res cells. The level of Mcl-1 protein is increased by ATRA treatment in NB4 and R4 cells, but not in HL-60 and HL-60/Res cells. Bfl-1/A1 mRNA is not expressed in these cell lines, however, its expression is markedly induced by ATRA treatment in NB4 and HL-60 cells, but not in R4 or HL-60/Res cells, which correlates with inhibition of apoptosis. Inhibiting Bfl-1/A1 mRNA upregulation in ATRA-pretreated NB4 cells using small interfering RNA (siRNA) partly recovers cell sensitivity to Dox-induced apoptosis. These data demonstrate that ATRA induction of Bfl-1/A1 in differentiated NB4 and HL-60 cells contributes to a loss of sensitivity to chemotherapy-induced apoptosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.
Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385–1393.
Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
Fenaux P, Chomienne C, Degos L . All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13–25.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328–5335.
Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004; 22: 63–71.
Niitsu N, Ishii Y, Matsuda A, Honma Y . Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine. Cancer Res 2001; 61: 178–185.
Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300–4310.
Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124–133.
Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264–269.
Waxman S, Scher BM, Hellinger N, Scher W . Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 1990; 50: 3878–3887.
Huang Y, Waxman S . Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 1998; 4: 2503–2509.
Miller Jr WH, Waxman S . Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002; 21: 3496–3506.
Chen C, Lin H, Karanes C, Pettit GR, Chen BD . Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis. Cancer Res 2000; 60: 4377–4385.
Lombet A, Zujovic V, Kandouz M, Billardon C, Carvajal-Gonzalez S, Gompel A et al. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family. Eur J Biochem 2001; 268: 1352–1362.
McCarthy JV, Fernandes RS, Gotter TG . Increased resistance to apoptosis associated with HL-60 myeloid differentiation status. Anticancer Res 1994; 14: 2063–2072.
Shore GC, Viallet J . Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 2005, 226–230.
Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002; 118: 521–534.
Monczak Y, Trudel M, Lamph WW, Miller Jr WH . Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997; 90: 3345–3355.
Yin W, Raffelsberger W, Gronemeyer H . Retinoic acid determines life span of leukemic cells by inducing antagonistic apoptosis-regulatory programs. Int J Biochem Cell Biol 2005; 37: 1696–1708.
Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM . High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730–737.
Kim H, Kim YN, Kim CW . Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene 2005; 24: 1252–1261.
Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol 2004; 125: 373–382.
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086.
Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller Jr WH . Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671–2682.
Li YP, Said F, Gallagher RE . Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha. Blood 1994; 83: 3298–3302.
Dai J, Weinberg RS, Waxman S, Jing Y . Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277.
Zhou L, Jing Y, Styblo M, Chen Z, Waxman S . Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 2005; 105: 1198–1203.
Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994; 85: 645–651.
Lin EY, Orlofsky A, Berger MS, Prystowsky MB . Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993; 151: 1979–1988.
Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H . Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680–686.
Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200.
Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8–13.
Laurent G, Jaffrezou JP . Signaling pathways activated by daunorubicin. Blood 2001; 98: 913–924.
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353.
Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5: 543–549.
Hafid-Medheb K, Poindessous-Jazat V, Augery-Bourget Y, Hanania N, Robert-Lezenes J . Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization. Cell Death Differ 1999; 6: 166–174.
Chatterjee D, Han ZG, Mendoza J, Goodglick L, Hendrickson EA, Pantazis P et al. Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bc-xL. Cell Growth Differ 1997; 6: 166–174.
Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL . Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL . Blood 1996; 87: 3837–3843.
Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96: 1496–1504.
Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96: 2907–2912.
Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N, Gibson SB . Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem 2003; 89: 1177–1192.
Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH et al. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 1998; 18: 4883–4898.
Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C . The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382–387.
D'Sa-Eipper C, Subramanian T, Chinnadurai G . bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996; 56: 3879–3882.
Carrio R, Lopez-Hoyos M, Jimeno J, Benedict MA, Merino R, Benito A et al. A1 demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death. Am J Pathol 1996; 149: 2133–2142.
Shim YH, Byun EK, Lee MJ, Huh J, Kim CW . Anti-apoptotic role of Bfl-1 in staurosporine-treated B-lymphoblastic cells. Int J Hematol 2000; 72: 484–490.
Cheng Q, Lee HH, Li Y, Parks TP, Cheng G . Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000; 19: 4936–4940.
Tabe Y, Konopleva M, Contractor R, Igari J, Andreeff M . Upregulation of MDR1 and induction of doxorubicin resistance by synergistic use of histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 2003; 102: 3200 Part 3201.
Fenaux P, Chomienne C, Degos L . Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2001; 14: 153–174.
Acknowledgements
This work was partly supported by NIH CA93533 and Samuel Waxman Cancer Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xia, L., Wurmbach, E., Waxman, S. et al. Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia 20, 1009–1016 (2006). https://doi.org/10.1038/sj.leu.2404198
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404198
Keywords
This article is cited by
-
TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1
Cell Death & Differentiation (2019)
-
Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells
British Journal of Cancer (2015)
-
Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells
Apoptosis (2013)
-
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1
Leukemia (2010)
-
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
BMC Cancer (2008)